Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Biotechnology, Inc. (VIR) will announce its first-quarter financial results on May 2, 2024, followed by a conference call. The update will be available on their website. Investors can join the call via webcast or phone.
04/11/2024 - 04:30 PM
SAN FRANCISCO --(BUSINESS WIRE)--
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio . Participants may access the conference call via webcast on the Events & Presentations page of Vir’s website at https://investors.vir.bio/events-presentations or listen in by dialing the U.S. toll free number (888) 800-8770 or international +1 (646) 307-1953, Conference ID: 756877. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411706041/en/
Media
Carly Scaduto
Senior Director, External Communications
cscaduto@vir.bio
+1 314-368-5189
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
+1 978-973-9986
Source: Vir Biotechnology, Inc.
When will Vir Biotechnology announce its first-quarter financial results?
Vir Biotechnology will announce its first-quarter financial results on May 2, 2024.
How can investors access the corporate update and financial results?
Investors can access the corporate update and financial results on the Press Releases section of Vir's website at www.vir.bio.
How can participants join the conference call?
Participants can join the conference call via webcast on the Events & Presentations page of Vir's website or by dialing the U.S. toll-free number (888) 800-8770 or international +1 (646) 307-1953, Conference ID: 756877.
Will a recorded version of the conference call be available?
Yes, a recorded version of the call will be available on the website approximately two hours after the event and will be archived for 30 days.
Vir Biotechnology Inc
NASDAQ:VIR
VIR Rankings
#5021 Ranked by Stock Gains
VIR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Commercial Services, Miscellaneous Commercial Services, Health Technology, Biotechnology
About VIR
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.